Suven Pharmaceuticals Share Price
Suven Pharmaceuticals Share Price Today
As of 15 Aug 2026, Suven Pharmaceuticals share price is ₹440.65. The stock opened at ₹444.95, compared to its previous close of ₹444.20. During today's trading session, Suven Pharmaceuticals share price moved in the range of ₹438.50 to ₹448.70, with an average price of ₹443.60 for the day. Looking at its last 52-week, the stock has touched a low of ₹266.70 and a high of ₹1,038.90. On the performance front, Suven Pharmaceuticals share price has increased by 39.62% over the last six months and is down 51.78% on a year-on-year basis.
Suven Pharmaceuticals Returns Calculator
About Suven Pharmaceuticals
Cohance Lifesciences Limited, formerly Suven Pharmaceuticals Limited, is an India-based technology-driven contract development and manufacturing organization (CDMO), providing integrated solutions in custom synthesis, process research and development (R&D), and manufacturing. The Company’s business units include pharmaceutical CDMO, specialty chemical CDMO, and active pharmaceutical ingredient (API) (including formulations). Its integrated CDMO model enables comprehensive molecule development and life cycle management for both pharmaceutical and specialty chemical partners. Its custom synthesis services include design and synthesis, synthesis of complex molecules, synthesis of reference standards, synthesis of impurities and metabolites, scale-up of existing synthetic routes, and process optimization and backward integration. Its process research services include route scouting, process development, process safety evaluation, analytical method development, and regulatory support.
Suven Pharmaceuticals Financial Highlights
- Revenue: Suven Pharmaceuticals reported revenue of ₹2,302.64 crore in FY26 vs ₹2,677.71 crore in FY25. It showed a decrease of 14.01% on a yearly basis.
- Operating Profit: Suven Pharmaceuticals reported an operating profit of ₹207.04 crore in FY26 vs ₹642.63 crore in FY25. It showed a decrease of 67.78% on a year-on-year basis.
- Net Profit: Suven Pharmaceuticals reported a net profit of ₹150.12 crore in FY26 vs ₹484.24 crore in FY25. It showed a decrease of 69.00% on a yearly basis.
Suven Pharmaceuticals Quarterly Result Highlights
- Suven Pharmaceuticals reported revenue of ₹434.51 crore in Jun 2026, compared with ₹617.28 crore in Mar 2026, representing a decrease of 29.61% on a quarter-on-quarter (QoQ) basis.
- Suven Pharmaceuticals reported an operating loss of ₹42.87 crore in Jun 2026, compared with ₹19.91 crore in Mar 2026, representing a decrease of 315.32% on a quarter-on-quarter (QoQ) basis.
- Suven Pharmaceuticals reported a loss of ₹45.19 crore in Jun 2026, compared with ₹8.31 crore in Mar 2026, reflecting a decrease of 643.80% on a QoQ basis.
- The earnings per share (EPS) of Suven Pharmaceuticals stood at ₹10.52 during Jun 2026.
| Sep 2025 | 6.51% |
|---|---|
| Dec 2025 | 6.02% |
| Mar 2026 | 5.59% |
| Jun 2026 | 6.50% |
Suven Pharmaceuticals Shareholder Returns
Suven Pharmaceuticals Share Price History
| Name | Mkt Cap Cr | P/E | P/B | ROE | D/E | ROCE | Book Value | Div. Yield | Turnover | EPS(TTM) |
|---|---|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries | 4,61,848.00 | 38.12 | 5.53 | 13.74% | 0.61 | 17.33% | 93.24 | 0.83% | 0.48 | 10.90 |
| Divis Laboratories | 2,25,648.00 | 77.15 | 13.46 | 15.32% | 0.00 | 19.56% | 629.49 | 0.35% | 0.55 | 98.19 |
| Torrent Pharmaceuticals | 1,84,109.00 | 85.40 | 21.89 | 25.49% | 1.69 | 13.85% | 222.76 | 0.70% | 0.49 | 58.70 |
| Cipla | 1,17,139.00 | 34.91 | 3.40 | 11.27% | 0.00 | 14.95% | 423.36 | 0.90% | 0.45 | 43.52 |
| Zydus Lifesciences | 1,13,715.00 | 24.76 | 4.19 | 18.59% | 0.31 | 17.35% | 237.30 | 0.09% | 0.33 | 35.38 |
| Lupin | 1,03,380.00 | 18.41 | 4.55 | 23.76% | 0.04 | 24.88% | 659.05 | 0.81% | 0.57 | 129.18 |
| Dr. Reddy's Laboratories | 1,00,328.00 | 31.52 | 2.64 | 11.07% | 0.18 | 12.54% | 377.96 | 0.67% | 0.41 | 38.68 |
| Mankind Pharma | 99,945.00 | 48.34 | 6.13 | 11.74% | 0.34 | 13.13% | 397.02 | 0.04% | 0.44 | 49.37 |
| Laurus Labs | 98,064.00 | 89.94 | 18.50 | 16.77% | 0.40 | 16.14% | 97.20 | 0.11% | 0.67 | 13.72 |
| Aurobindo Pharma | 96,296.90 | 25.95 | 2.54 | 9.25% | 0.19 | 11.76% | 391.14 | 0.24% | 0.38 | 41.58 |
Suven Pharmaceuticals Financials
Income Statement · Consolidated
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|
| Revenue | ₹1,197.58 | ₹1,051.35 | ₹1,340.33 | ₹1,320.22 |
| Other Income | ₹58.56 | ₹61.91 | ₹46.36 | ₹92.38 |
| Total Revenue | ₹1,256.14 | ₹1,113.26 | ₹1,386.69 | ₹1,412.60 |
| Total Expenses | ₹912.22 | ₹707.59 | ₹826.96 | ₹786.12 |
| Profit Before Tax | ₹343.92 | ₹405.67 | ₹559.73 | ₹667.59 |
| Tax | ₹79.15 | ₹105.39 | ₹148.44 | ₹213.78 |
| Profit After Tax | ₹264.77 | ₹300.28 | ₹411.29 | ₹453.80 |
| EPS - Basic | ₹10.52 | ₹11.80 | ₹16.16 | ₹17.83 |
| EPS - Diluted | ₹10.45 | ₹11.80 | ₹16.16 | ₹17.83 |
Cash Flow · Consolidated
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|
| Profit before tax | ₹343.92 | ₹405.67 | ₹559.73 | ₹667.59 |
| Income before WC changes | ₹403.74 | ₹421.02 | ₹597.19 | ₹708.22 |
| Change in Assets | -₹73.84 | ₹70.44 | ₹59.22 | -₹228.99 |
| Change in Liabilities | ₹41.70 | -₹23.03 | -₹53.45 | ₹35.02 |
| Change in WC | -₹32.14 | ₹47.41 | ₹5.77 | -₹193.97 |
| Cash flow from Operations | ₹288.16 | ₹358.48 | ₹457.20 | ₹330.00 |
| Cash flow from Investing | -₹255.30 | -₹362.25 | -₹195.01 | -₹136.21 |
| Cash flow from Financing | ₹3.32 | -₹13.80 | -₹241.95 | -₹156.41 |
| Total Cash Flow | ₹36.18 | -₹17.57 | ₹20.24 | ₹37.38 |
| Cash (Start of the year) | ₹47.23 | ₹64.80 | ₹44.56 | ₹7.18 |
| Cash (End of the year) | ₹85.40 | ₹47.23 | ₹64.80 | ₹44.56 |
Balance Sheet · Consolidated
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|
| Non-Current Assets | ₹2,143.16 | ₹990.90 | ₹954.70 | ₹701.66 |
| Current Assets | ₹888.59 | ₹1,263.19 | ₹1,011.05 | ₹1,127.93 |
| Total Assets | ₹3,031.75 | ₹2,254.09 | ₹1,965.74 | ₹1,829.59 |
| Current Liabilities | ₹365.19 | ₹106.90 | ₹158.77 | ₹210.29 |
| Net Current Asset | ₹523.40 | ₹1,156.29 | ₹852.28 | ₹917.64 |
| Non-Current Liabilities | ₹825.92 | ₹96.53 | ₹71.79 | ₹92.11 |
| Equity Capital | ₹1,840.64 | ₹2,050.66 | ₹1,735.18 | ₹1,527.18 |
| Total Equity & Liabilities | ₹3,031.75 | ₹2,254.09 | ₹1,965.74 | ₹1,829.59 |
Income Statement · Standalone
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|
| Revenue | ₹1,093.51 | ₹1,051.35 | ₹1,330.08 | ₹1,320.22 |
| Other Income | ₹53.98 | ₹56.61 | ₹44.55 | ₹187.79 |
| Total Revenue | ₹1,147.49 | ₹1,107.96 | ₹1,374.63 | ₹1,508.01 |
| Total Expenses | ₹796.14 | ₹707.54 | ₹795.24 | ₹785.56 |
| Profit Before Tax | ₹351.35 | ₹400.42 | ₹579.39 | ₹722.45 |
| Tax | ₹79.64 | ₹103.95 | ₹146.79 | ₹164.35 |
| Profit After Tax | ₹271.71 | ₹296.47 | ₹432.60 | ₹558.10 |
| EPS - Basic | ₹10.67 | ₹11.65 | ₹16.99 | ₹21.92 |
| EPS - Diluted | ₹10.62 | ₹11.65 | ₹16.99 | ₹21.92 |
Cash Flow · Standalone
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|
| Profit before tax | ₹351.35 | ₹400.42 | ₹579.39 | ₹722.45 |
| Income before WC changes | ₹392.58 | ₹417.56 | ₹615.08 | ₹612.26 |
| Change in Assets | -₹69.82 | ₹90.72 | ₹79.68 | -₹224.37 |
| Change in Liabilities | ₹58.65 | -₹23.56 | -₹56.15 | ₹33.74 |
| Change in WC | -₹11.17 | ₹67.16 | ₹23.53 | -₹190.63 |
| Cash flow from Operations | ₹301.03 | ₹376.20 | ₹492.82 | ₹269.89 |
| Cash flow from Investing | -₹320.94 | -₹362.40 | -₹236.86 | -₹90.36 |
| Cash flow from Financing | ₹20.81 | -₹39.99 | -₹243.14 | -₹156.41 |
| Total Cash Flow | ₹0.90 | -₹26.19 | ₹12.81 | ₹23.12 |
| Cash (Start of the year) | ₹18.46 | ₹44.65 | ₹30.21 | ₹7.09 |
| Cash (End of the year) | ₹19.36 | ₹18.46 | ₹43.02 | ₹30.21 |
Balance Sheet · Standalone
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|
| Non-Current Assets | ₹1,879.05 | ₹990.65 | ₹1,003.21 | ₹695.93 |
| Current Assets | ₹708.76 | ₹1,224.23 | ₹955.12 | ₹1,108.96 |
| Total Assets | ₹2,587.81 | ₹2,214.88 | ₹1,958.33 | ₹1,804.89 |
| Current Liabilities | ₹213.53 | ₹117.15 | ₹154.18 | ₹209.00 |
| Net Current Asset | ₹495.23 | ₹1,107.08 | ₹800.94 | ₹899.96 |
| Non-Current Liabilities | ₹58.73 | ₹69.38 | ₹54.77 | ₹75.19 |
| Equity Capital | ₹2,315.55 | ₹2,028.35 | ₹1,749.38 | ₹1,520.69 |
| Total Equity & Liabilities | ₹2,587.81 | ₹2,214.88 | ₹1,958.33 | ₹1,804.89 |
| 14 Aug | 3L |
|---|---|
| 13 Aug | 6L |
| 12 Aug | 5L |
| 11 Aug | 22L |
| 10 Aug | 13L |
| Average | 10L |
Popular Stocks
Suven Pharmaceuticals Share Price FAQs
What is Suven Pharmaceuticals share price today?
Suven Pharmaceuticals share price is ₹440.65 as on 14 Aug, 2026, 15:56 IST.
How has the Suven Pharmaceuticals share price performed in the past?
In the last 1 year, Suven Pharmaceuticals delivered a return of -51.78%. The Suven Pharmaceuticals share price hit a high of ₹1,038.90 and low of ₹266.70.
How much is the Mutual Fund shareholding in Suven Pharmaceuticals shares?
The Mutual Fund Shareholding in Suven Pharmaceuticals was 18.21% at the end of Jun 2026.
What is the the 52-week high and low of Suven Pharmaceuticals shares ?
The 52-week high and low of Suven Pharmaceuticals share is ₹1,038.90 and ₹266.70 as of 14 Aug, 2026.
What is the market cap of Suven Pharmaceuticals?
The market capitalisation of Suven Pharmaceuticals is ₹16,872.50 Crores as on 14 Aug, 2026.
What are the stock symbols of Suven Pharmaceuticals?
The stock symbol of Suven Pharmaceuticals is COHANCE on the NSE, 543064 on the BSE, and the ISIN is INE03QK01018.
What was yesterday's closing price of Suven Pharmaceuticals shares ?
Suven Pharmaceuticals shares closed yesterday at ₹444.20 on NSE & ₹444.40 on BSE
How to buy Suven Pharmaceuticals shares?
To buy Suven Pharmaceuticals shares, open a demat account with Upstox and complete the KYC process. Once your account is set up, search for the stock and place your order.
Can I buy Suven Pharmaceuticals shares on Holidays?
No, shares of Suven Pharmaceuticals or any other publicly traded company cannot be bought or sold on holidays when the stock exchanges are closed. You can only buy or sell Suven Pharmaceuticals shares on days when the stock exchanges are open for trading. It's important to check the NSE & BSE holidays calendar, before placing any trades to avoid any inconvenience.
What is the PE and PB ratio of Suven Pharmaceuticals?
The PE and PB ratio of Suven Pharmaceuticals is 288.24 and 4.31 respectively, as on 14 Aug, 2026, 15:56 IST.



